Medical Developments International Limited · ASX:MVP
Medical Developments International — H1 FY2025 Earnings Presentation
19 slides from Medical Developments International's earnings presentation, Feb 20, 2025
Slide 1: FY25 Half Year Results
ASX:MVP FY25 HALF YEAR RESULTS 20 February 2025
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 108340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 3: FY25 Half Year Results
FY25 Half Year Results Revenue Pain Management revenue Respiratory revenue $20.0m $13.1m $6.9m +33% +37% +26% Underlying EBIT Reported NPAT Free cashflow $0.2m profit $0.3m profit $1.3m (outflow) (pcp $7.8m1 loss) (pcp $10.9m loss) +$6.8m 3 1. Underlying EBIT in the prior period excludes a $5.1 mill
Slide 4: Key messages
Key messages Financial performance strongly improved, delivery of strategy progressing • Group revenue of $20.0m (+33%) with improved results in Pain Management and Respiratory FY25 first half results • Margin improvements of $2.6m from enhanced pricing, with $3.5m annual benefits expected Margins,
Slide 5: Strategic priorities
Strategic priorities FY25 strategic priorities on-track FY25 strategic priorities Progress Improve margins through pricing and • Annualised margin improvement of $3.5 million delivered through higher pricing operational efficiency • Cost reductions of ~$4 million delivered through efficiency Acceler
Slide 6: Improve margins through pricing and efficiency
Improve margins through pricing and efficiency Annualised benefits of $7.5 million delivered Growth strategy FY25 progress • Achievement of margins that fully reflect the value proposition of 9 Annualised pricing benefits of ~$3.5 million, including: Penthrox® in all markets over time • Higher prici
Slide 7: Accelerate penetration of Penthrox in Australia
Accelerate penetration of Penthrox in Australia ® Medical led engagement approach to promote faster product adoption over time and support growth in global markets Growth strategy FY25 progress • Increase medical engagement 9 Encouraging growth in hospital segment, with demand up 52% • Maintain mome
Slide 8: Grow Penthrox in global markets
Grow Penthrox in global markets ® Leveraging a capital-light partner supported go-to-market strategy in a targeted manner Growth strategy FY25 progress • Strong partner engagement and knowledge exchange, including 9 European in-market demand up 22% in 1H FY25 versus the pcp support with external med
Slide 9: Results
Ee = =) 7) Lu Oo
Slide 10: Results summary
FY25 Half Year Results summary $million 1H24 1H25 Change $m Commentary Revenue 15.1 20.0 4.9 • Group revenue up 33% Underlying EBIT (7.8) 0.2 8.0 • Pain Management revenue up 37% driven by Underlying Adjustments (before tax) 1 (5.1) - 5.1 improved underlying demand, higher pricing Reported EBIT (12.
Slide 11: Pain Management segment revenue
FY25 Half Year Pain Management segment revenue Revenue up 37%, higher volumes in Europe and Australia and strongly improved pricing $million 1H24 1H25 Change % Commentary Europe 2.6 4.6 83% Europe Australia 5.8 7.3 25% Rest of World 1.1 1.1 (3%) • Revenue up 83%, with growth in underlying demand of
Slide 12: Respiratory segment revenue
FY25 Half Year Respiratory segment revenue Revenue up 26%, continued share growth in US and improved demand in Australia $million 1H24 1H25 Change % Commentary Australia 1.6 1.9 25% Australia USA 3.3 4.0 23% • Stronger demand conditions Europe 0.2 0.7 252% Rest of World 0.5 0.3 (42%) • Market share
Slide 13: EBIT bridge
FY25 Half Year EBIT bridge Pricing and efficiency drive step-change in earnings improvement Underlying EBIT Commentary ($million) Pricing and efficiency • Stronger pricing in Pain Management, particularly for Penthrox® in Australia, the UK 1H24 1H25 Underlying Pricing Efficiency Penthrox Respiratory
Slide 14: Balance sheet and cashflow
FY25 Half Year Balance sheet and cashflow Free cashflow improved $6.8 million Commentary $million 1H24 1H25 Change Operating cashflow Operating cash flow (6.5) (0.8) 5.7 • Strongly improved operating earnings • Disciplined working capital management with strong Capital expenditure (1.6) (0.5) 1.1 cu
Slide 15: Closing remarks and outlook
Closing remarks and outlook On track to deliver positive operating cashflow by end of FY25 Margins, earnings and cashflow strongly improved. Good progress in delivering key strategic priorities. Phasing and movements in foreign exchange rates are expected to result in earnings that are lower in the
Slide 16: Appendices
APPENDICES
Slide 17: Business overview
Appendices Business overview The Pain Management segment delivers 65% of Group revenue, driven by demand for Penthrox® in Australia and global markets Pain Management Respiratory Supplies pharmacies, medical clinics and hospitals with a range of Description Manufactures Penthrox®, an inhaled, needle
Slide 18: Penthrox overview
Appendices Penthrox overview ® Efficacy, safety and administration benefits of Penthrox® deliver positive patient outcomes and lower overall customer costs1-5 • Inhaled needle-free analgesic 1 The iconic Green Whistle • Non-opioid1 • Portable, self administered device1 • Effective pain relief within
Slide 19: Reconciliation between underlying EBITDA and net loss after tax
Appendices Reconciliation between underlying EBITDA and net loss after tax $million 1H24 1H25 Notes 1H24 Underlying EBITDA (6.3) 1.8 An acceleration of share-based payment expense of Depreciation and amortisation expense (1.5) (1.6) $5.1m relating to the cancellation of all share options held by t
Medical Developments International — H1 FY2025 Earnings Presentation on 6ix